Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Background - Pertuzumab (P) combined with trastuzumab (H)-based chemotherapy improves efficacy in early and advanced HER2-positive breast cancer. We assessed the tolerability, with particular focus on cardiac safety, of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early br...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 May 2013
|
| In: |
Annals of oncology
Year: 2013, Volume: 24, Issue: 9, Pages: 2278-2284 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdt182 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdt182 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419369297 
|
| Author Notes: | A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J.H. Seo, Y. -F. Tsai, J. Ratnayake, V. McNally, G. Ross & J. Cortés |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1762676206 | ||
| 003 | DE-627 | ||
| 005 | 20220820014239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210712s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdt182 |2 doi | |
| 035 | |a (DE-627)1762676206 | ||
| 035 | |a (DE-599)KXP1762676206 | ||
| 035 | |a (OCoLC)1341418398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 245 | 1 | 0 | |a Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer |b a randomized phase II cardiac safety study (TRYPHAENA) |c A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J.H. Seo, Y. -F. Tsai, J. Ratnayake, V. McNally, G. Ross & J. Cortés |
| 264 | 1 | |c 22 May 2013 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.07.2021 | ||
| 520 | |a Background - Pertuzumab (P) combined with trastuzumab (H)-based chemotherapy improves efficacy in early and advanced HER2-positive breast cancer. We assessed the tolerability, with particular focus on cardiac safety, of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer. - Patients and methods - In this multicenter, open-label phase II study, patients with operable, locally advanced, or inflammatory breast cancer were randomized 1 : 1 : 1 to receive six neoadjuvant cycles q3w (Arm A: 5-fluorouracil, epirubicin, cyclophosphamide [FEC] + H + P ×3 → docetaxel [T] + H + P ×3; Arm B: FEC ×3 → T + H + P ×3; Arm C: T + carboplatin + H [TCH]+P ×6). pCR was assessed at surgery and adjuvant therapy given to complete 1 year of H. - Results - Two hundred twenty-five patients were randomized. During neoadjuvant treatment, two patients (2.7%; Arm B) experienced symptomatic left ventricular systolic dysfunction (LVSD) and 11 patients (Arm A: 4 [5.6%]; Arm B: 4 [5.3%]; Arm C: 3 [3.9%]) had declines in left ventricular ejection fraction of ≥10% points from baseline to <50%. Diarrhea was the most common adverse event. pCR (ypT0/is) was reported for 61.6% (Arm A), 57.3% (Arm B), and 66.2% (Arm C) of patients. - Conclusion - The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD. | ||
| 650 | 4 | |a early breast cancer | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a LVSD | |
| 650 | 4 | |a neoadjuvant | |
| 650 | 4 | |a pertuzumab | |
| 650 | 4 | |a trastuzumab | |
| 700 | 1 | |a Chia, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hickish, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harvey, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eniu, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hegg, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tausch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seo, J. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tsai, Y. -F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ratnayake, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a McNally, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ross, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortés, J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 24(2013), 9, Seite 2278-2284 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer a randomized phase II cardiac safety study (TRYPHAENA) |
| 773 | 1 | 8 | |g volume:24 |g year:2013 |g number:9 |g pages:2278-2284 |g extent:7 |a Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer a randomized phase II cardiac safety study (TRYPHAENA) |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdt182 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753419369297 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210712 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1762676206 |e 3947819943 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J.H. Seo, Y. -F. Tsai, J. Ratnayake, V. McNally, G. Ross & J. Cortés"]},"note":["Gesehen am 12.07.2021"],"person":[{"role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"},{"given":"S.","display":"Chia, S.","family":"Chia","role":"aut"},{"family":"Hickish","role":"aut","given":"T.","display":"Hickish, T."},{"role":"aut","family":"Harvey","display":"Harvey, V.","given":"V."},{"role":"aut","family":"Eniu","display":"Eniu, A.","given":"A."},{"given":"R.","display":"Hegg, R.","family":"Hegg","role":"aut"},{"role":"aut","family":"Tausch","display":"Tausch, C.","given":"C."},{"role":"aut","family":"Seo","display":"Seo, J. H.","given":"J. H."},{"display":"Tsai, Y. -F.","given":"Y. -F.","role":"aut","family":"Tsai"},{"family":"Ratnayake","role":"aut","given":"J.","display":"Ratnayake, J."},{"family":"McNally","role":"aut","given":"V.","display":"McNally, V."},{"display":"Ross, G.","given":"G.","role":"aut","family":"Ross"},{"display":"Cortés, J.","given":"J.","family":"Cortés","role":"aut"}],"recId":"1762676206","physDesc":[{"extent":"7 S."}],"id":{"eki":["1762676206"],"doi":["10.1093/annonc/mdt182"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","subtitle":"a randomized phase II cardiac safety study (TRYPHAENA)"}],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"22 May 2013"}],"relHost":[{"origin":[{"dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-"}],"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2003498-2"],"eki":["320428796"],"issn":["1569-8041"]},"recId":"320428796","disp":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer a randomized phase II cardiac safety study (TRYPHAENA)Annals of oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"pubHistory":["1.1990 -"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"part":{"volume":"24","year":"2013","extent":"7","pages":"2278-2284","issue":"9","text":"24(2013), 9, Seite 2278-2284"}}]} | ||
| SRT | |a SCHNEEWEISPERTUZUMAB2220 | ||